Sebastian Grosicki
Overview
Explore the profile of Sebastian Grosicki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
4641
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rampal R, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds A, et al.
Nat Med
. 2025 Mar;
PMID: 40065169
Janus kinase (JAK) inhibitors provide limited depth and durability of response in myelofibrosis. We evaluated pelabresib-a bromodomain and extraterminal domain (BET) inhibitor-plus ruxolitinib (a JAK inhibitor) compared with placebo plus...
2.
Usmani S, Facon T, Hungria V, Bahlis N, Venner C, Braunstein M, et al.
Nat Med
. 2025 Feb;
PMID: 39948407
No abstract available.
3.
Usmani S, Facon T, Hungria V, Bahlis N, Venner C, Braunstein M, et al.
Nat Med
. 2025 Feb;
PMID: 39910273
Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide...
4.
Suska A, Tyczynska A, Zaucha J, Kopinska A, Helbig G, Markiewicz M, et al.
Eur J Haematol
. 2025 Jan;
PMID: 39777794
Objectives: The study evaluated the impact of lifestyle and environmental exposure on the etiology of multiple myeloma (MM). Methods: A multicenter case-control study was conducted in 20 hematology centers and...
5.
Shadman M, Munir T, Robak T, Brown J, Kahl B, Ghia P, et al.
J Clin Oncol
. 2024 Dec;
43(7):780-787.
PMID: 39647999
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with...
6.
Brown J, Eichhorst B, Lamanna N, OBrien S, Tam C, Qiu L, et al.
Blood
. 2024 Sep;
144(26):2706-2717.
PMID: 39316666
The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis...
7.
Zielinska P, Wieczorkiewicz-Kabut A, Bialas K, Koclega A, Gruenpeter K, Kopinska A, et al.
Ann Hematol
. 2024 Jun;
103(8):3095-3104.
PMID: 38878171
Haploidentical stem cell transplantation (haplo-SCT) using post-transplantation cyclophosphamide (post-Cy) is considered a reasonable therapeutic option for patients who lack matched donor or who urgently need transplant procedure due to high...
8.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho P, et al.
N Engl J Med
. 2024 Jun;
391(5):393-407.
PMID: 38828933
Background: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies. Methods: In...
9.
Kiladjian J, Marin F, Al-Ali H, Alvarez-Larran A, Beggiato E, Bieniaszewska M, et al.
Ann Hematol
. 2024 Mar;
103(7):2299-2310.
PMID: 38438627
Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim to normalize hematological parameters and reduce...
10.
Brown J, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, et al.
Future Oncol
. 2023 Dec;
20(12):717-726.
PMID: 38088119
What Is This Summary About?: This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at...